Having benefited financially from the increased demand from the coronavirus pandemic in the first quarter, Sandoz saw a reversal of fortune in Q2 as sales fell by more than one-tenth as reported, as the company explained to Generics Bulletin.
Sandoz’s global biosimilars portfolio will help the company achieve overall low-single-digit turnover growth in the second half of 2020, CEO Richard Saynor has forecast, as their impact helped mitigate somewhat a significant COVID-19-inspired downturn in sales in the second quarter.
An anticipated reversal of COVID-19-related stocking in the three months to 30 June, affecting new patient starts and demand for the company’s retail generics, contributed to Sandoz’s sales plunging
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
